Brief: Innocan Pharma Reports Full Year 2024 Results With Revenues More Than Doubling To Us $29.4 Million
31/03/2025 23:20
March 31 (Reuters) - Innocan Pharma Corp INNO.CD: INNOCAN PHARMA REPORTS FULL YEAR 2024 RESULTS WITH REVENUES MORE THAN DOUBLING TO US $29.4 MILLION Source text: ID:nCNWcT8R3a Further company coverage: INNO.CD ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innocan Pharma
See all newsBrief: Innocan Pharma Corp To Offer Up To 3.75 Million Units In IPO - SEC Filing
Brief: Innocan Pharma Announces Promising Results Of LPT-CBD Administered To Gottingen Minipigs
Brief: Innocan Pharma Corp - Liposomal Cbd Injection Technology Patent Allowed In Japan
Brief: Innocan Pharma Corp Now Sees U.S IPO Of 1.1 Million Units - SEC Filing
Brief: Innocan Pharma Announces Details Of Proposed Share Consolidation